Hematopoiesis News Volume 5.44 | Nov 25 2014

Lymph Node Stromal Cells Constrain Immunity via MHC Class II Self-Antigen Presentation
Investigators show that MHC-II expression on lymph node stromal cells is additionally required for homeostatic maintenance of regulatory T cells and maintenance of immune quiescence. [Elife]
Abstract | Download Full Article

Tauroursodeoxycholic Acid, a Bile Acid, Promotes Blood Vessel Repair by Recruiting Vasculogenic Progenitor Cells
Tauroursodeoxycholic acid (TUDCA) induced dissociation of CD34⁺ hematopoietic stem cells from stromal cells by reducing adhesion molecule expression. TUDCA increased CD34⁺/Sca1⁺ progenitors in mice peripheral blood (PB), and CD34⁺, CD31⁺, and c-kit⁺ progenitors in human PB. [Stem Cells] Abstract

A Stromal Cell-Free Culture System Generates Mouse Pro-T Cells that Can Reconstitute T-Cell Compartments In Vivo
Scientists describe a novel stromal cell-free culture system in which Lineage^–Sca1⁺c-kit⁺ bone marrow hematopoietic progenitors very efficiently differentiate into pro-T cells. [Eur J Immunol] Abstract

Plasma CC-Chemokine Ligand 28 Level Is Correlated with Hematopoietic Stem Cells in Human Cord Blood
To reveal the effect of CC-chemokine ligand 28 (CCL28) on hematopoietic cells in human cord blood (CB) at birth, researchers measured CCL28 in frozen CB plasma, which was preserved as a reference sample for cryopreserved CB units for hematopoietic stem cells transplantation. [Transfusion] Abstract

Cell Fate Decisions in Malignant Hematopoiesis: Leukemia Phenotype Is Determined by Distinct Functional Domains of the MN1 Oncogene
Investigators dissected the functional aspects of different protein regions of the MN1 oncogene and their effect on the leukemic phenotype, building on the ability of MN1 to induce leukemia without accompanying mutations. [PLoS One] Full Article

CLINICAL RESEARCH

A Phase I Study of the Safety, Pharmacokinetics and Anti-Leukemic Activity of the Anti-CD123 Monoclonal Antibody CSL360 in Relapsed, Refractory or High-Risk Acute Myeloid Leukemia
This Phase I study assessed safety, pharmacokinetics and bioactivity of weekly intravenous CSL360 for 12 weeks in 40 patients with advanced acute myeloid leukemia across five dose levels. [Leuk Lymphoma] Abstract

Lower Dose of Antithymocyte Globulin Does Not Increase Graft-versus-Host Disease in Patients Undergoing Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplant
The appropriate dose of antithymocyte globulin to be utilized in reduced-intensity conditioning allogeneic hematopoietic stem cell transplant is as yet unknown. Researchers retrospectively compared patients who received 7.5 mg/kg and 6 mg/kg. [Leuk Lymphoma] Abstract

Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.

From our sponsor: Learn about assays for cord blood. Download the free technical bulletin.

BerGenBio Receives Orphan-Drug Designation from FDA for BGB324 in the Treatment of Acute Myeloid Leukemia
BerGenBio AS announced that the US Food and Drug Administration (FDA) has granted orphan-drug designation for BGB324 for treatment of acute myeloid leukemia (AML). Earlier BerGenBio announced that the first patient has been dosed in its multi-center Phase Ib trial of BGB324, a selective inhibitor of Axl, in patients with AML. [BerGenBio AS] Press Release

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the hematopoiesis community.

NEW Clinical Laboratory Scientist – Umbilical Cord Blood Processing (California Cryobank)

Head of Cellular and Molecular Therapies Laboratory (NHS Blood & Transplant)

Postdoctoral Researcher – Chromatin and Epigenetic Regulation (Van Andel Research Institute)

Postdoctoral Position – Post-Transcriptional Control of Gene Expression in Hematopoietic Stem Cells (Lund University)

Postdoctoral Fellow – Stem Cell Biology Gene Expression and Regulation (The University of Texas Medical School At Houston)

PhD Studentship – Discovery of Key Regulators of Normal and Leukemic Stem Cell Functions (University of Edinburgh)

Postdoctoral Research Associate – Mechanisms Underlying Hematopoiesis and Leukemogenesis (University of Wisconsin School of Medicine and Public Health)

Postdoctoral Position – Molecular Properties of Leukemic Stem Cells (BC Cancer Agency)

Stem Cell Biology Program Director (Blood Research Institute of BloodCenter of Wisconsin)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.